JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Strona główna・Stock List・Novavax Inc

Novavax Inc

Closed

SectorHealthcare

6.8 1.19

Buy Sell

Overview

Share price change

24h

Current

Min

6.67

Max

6.97

Key metrics
By Trading Economics
Income	600M 519M
Sales	578M 667M
P/E Sector Avg	2.455 34.393
Profit margin	77.798
Employees	952
EBITDA	569M 516M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+45.19% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2025

Market Stats
By TradingEconomics
Market Cap	78M 1.1B
Previous open	5.61
Previous close	6.8

News Sentiment

By Acuity

53%

47%

311 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

5.692 / 6.039 Support & Resistance

Novavax Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 17:06 UTC

Major Market Movers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

4 lut 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

11 lis 2024, 14:05 UTC

Major Market Movers

Novavax to Move Forward With Covid-19, Influenza Vaccine After FDA Lifts Clinical Hold

16 paź 2024, 12:59 UTC

Major Market Movers

Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines; Shares Drop

19 maj 2025, 14:30 UTC

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

45.19% upside

12 Months Forecast

Average 9.8 USD 45.19%

High 19 USD

Low 6 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Novavax Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.692 / 6.039Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

311 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.